If drugmakers succeed in a campaign to pass state laws governing dispensing of less costly biosimilar drugs, patients and taxpayers will pay the price, PCMA President and CEO Mark Merritt said. "Campaigning to restrict the use of biosimilars enriches brand manufacturers at the expense of the employers, public health programs and patients who need access to lower-cost medicines," Merritt said.

Related Summaries